Skip to content
sellWeak cluster of 410b5-1 plan

Joseph Douglas Lyon sold $398k of CORT

See Remarks at CORCEPT THERAPEUTICS INC. 5,000 shares at an average of $79.53, traded Dec 1, 2025, filed Dec 3, 2025.

Warning score
21
Value
$398k
5,000 shares
Holdings after
10,277
-33% from before
From 52-week low
+60%
low $49.85, close $79.78
From 52-week high
-30%
high $114.22, as of Dec 1, 2025

Score components

  • Role
    Officer
    +15
  • Trade size
    $398k at market
    +16
  • Share of holdings sold
    Sold 33% of holdings
    +10
  • Cluster
    4 insiders selling within 14 days
    +15
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

This signal so far: 1m -54.3%, 3m -57.3%, 6m -13.2%.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

CORTOct 12, 2026 · close 121.19
Since filing Dec 3, 2025: +44.8%SPY +15.0% · excess +29.9%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001193125-25-307229, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Dec 1, 2025MOption exercise
Common Stock10b5-1
+5,000$13.56$68k15,277Dec 3, 2025
Dec 1, 2025SOpen-market sale
Common Stock10b5-1
-5,000$79.53$398k10,277Dec 3, 2025
Dec 1, 2025AGrant or award
Common Stock10b5-1
+178$79.78$14k10,455Dec 3, 2025
Dec 1, 2025AGrant or award
Common Stock10b5-1
+178$0.00$010,633Dec 3, 2025
Dec 2, 2025FTax withholding
Common Stock10b5-1
-110$79.78$8,77610,523Dec 3, 2025
Dec 1, 2025MOption exercise
Stock option (right to buy)derivative10b5-1
-5,000$0.00$011,571Dec 3, 2025

Related signals

Other insiders at CORCEPT THERAPEUTICS INC and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
40Moderate
CORTsell 310b5-1
CORCEPT THERAPEUTICS INC
Sean Maduck
See Remarks
$2.9M
25,000 shares
-242%
40Moderate
CORTsell 310b5-1
CORCEPT THERAPEUTICS INC
Joseph Douglas Lyon
See Remarks
$1.2M
10,000 shares
-154%
45Moderate
CORTsell 310b5-1
CORCEPT THERAPEUTICS INC
Roberto Wandenkolk Vieira
President, Oncology
$967k
8,333 shares
-68%
20Weak
CORTsell 310b5-1
CORCEPT THERAPEUTICS INC
Roberto Wandenkolk Vieira
President, Oncology
$30k
296 shares
-7%
35Weak
CORTsell 410b5-1
CORCEPT THERAPEUTICS INC
James N Wilson
director
$1.1M
10,000 shares
-1%
40Moderate
CORTsell 410b5-1
CORCEPT THERAPEUTICS INC
Joseph Douglas Lyon
See Remarks
$1.1M
10,000 shares
-64%
45Moderate
CORTsell 510b5-1
CORCEPT THERAPEUTICS INC
Roberto Wandenkolk Vieira
President, Oncology
$6.5M
58,333 shares
-93%
40Moderate
CORTsell 610b5-1
CORCEPT THERAPEUTICS INC
Sean Maduck
See Remarks
$2.9M
25,000 shares
-72%
60Notable
CORTsell 6
CORCEPT THERAPEUTICS INC
Kimberly Park
director
$3.3M
26,685 shares
-100%
40Moderate
CORTsell 610b5-1
CORCEPT THERAPEUTICS INC
Sean Maduck
See Remarks
$3.9M
30,955 shares
-76%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Joseph Douglas Lyon sold $398k of CORT | InsiderTell